SGLT2 inhibitors increase the risk of euglycemic diabetic ketoacidosis via several pathways: stimulating glucagon release from pancreatic Î±-cells, diminishing urine excretion of ketone bodies, and causing a carb-starvation state in spite of typical blood sugar levels.